This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

DESTINY-Breast06 - T-DXd vs. Physician’s Choice of Chemotherapy in HR+/HER2-Low/Ultralow mBC After Endocrine Therapy

736 views
June 18, 2024
Comments 0
Login to view comments. Click here to Login